Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Miravant's SnET2 Requires Additional Clinical Trial For Macular Degeneration

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA needs further confirmation before granting full approval to the photosensitive drug/photodynamic therapy combination, Miravant says. The firm is seeking approval for both predominantly and minimally classic AMD.

You may also be interested in...



Miravant Plans Photrex Confirmatory Macular Degeneration Trial

The trial, to be conducted under a special protocol assessment with FDA, will be one year with another year for confirmatory results. Agency's September 2004 "approvable" letter for the photodynamic therapy requested an additional study. Miravant is also planning combination studies with other age-related macular degeneration agents.

Miravant Plans Photrex Confirmatory Macular Degeneration Trial

The trial, to be conducted under a special protocol assessment with FDA, will be one year with another year for confirmatory results. Agency's September 2004 "approvable" letter for the photodynamic therapy requested an additional study. Miravant is also planning combination studies with other age-related macular degeneration agents.

Concomitant Use Of Macugen With Visudyne Appears Safe, Cmte. Says

Concomitant use of Pfizer/Eyetech's Macugen (pegatanib) with Novartis/QLT's Visudyne (verteporfin) does not pose safety concerns, FDA's Dermatologic & Ophthalmic Drugs Advisory Committee concluded Aug. 27.

Topics

UsernamePublicRestriction

Register

OM013658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel